ClinicalTrials.gg
Not yet recruitingNCT05028959FEMMESUpdated Aug 31, 2021

Hormonal Status, Performance and Health in Elite Female Athlete

An interventional study of Multidisciplinary monitoring of healthy women in Healthy, sponsored by Université Paris-Saclay-Assistance publique des hôpitaux de Paris. Not yet recruiting. Open to female participants aged 16 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-31.

Sponsored by Université Paris-Saclay-Assistance publique des hôpitaux de Paris · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by May 2023, 3 years 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
16 Years to 30 Years
Sex
Female
01

Study summary

The repercussions of the hormonal status of high-level sportswomen on their performance and health as well as on the Athlete's Biological Passport (ABP) have been little studied and remain poorly known. The investigators therefore propose to contribute to the improvement of current knowledge by determining, thanks to the implementation of a multidisciplinary monitoring, with the use of various tests and matrices, in female elite athletes and recreational athletes (control group):

    1. the impact of cycle phase, absence of cycle or contraceptive use on physical and psychological performance, health as well as on ABP;
    1. the potential confounding effects of the athlete's environment
    1. correlations between the different matrices analyzed
Read the detailed description

Volunteers to be studied: 80 healthy female subjects (16 to 30 years old), divided into 2 groups:

Group 1: 60 athletes, from different sports disciplines, in amenorrhea, with menstrual cycle or taking contraceptives

Group 2: 20 leisure sports subjects with menstrual cycle or taking contraceptives

Following the oral and written information of the project, the subjects have a minimum of 15 days of reflection before signing the written consent form. They will have the possibility, at any time, to voluntarily interrupt the study without having to justify themselves.

Investigations to be performed:

  1. Annual complete clinical examination :
  2. "Out-of-competition" follow-up, time frame 6 months

    • medical, nutritional and respiratory monitoring
    • biological monitoring
    • psychological monitoring
    • performance monitoring
  3. Non-invasive "in-competition" monitoring, only for Group 1, once in a year on the day before/after a major competition:

    • biological monitoring
    • psychological monitoring
    • performance monitoring (interview)
02

Conditions studied

  • Healthy

Browse trials for

Keywords

  • female elite athlete
  • menstrual phase
  • amenorrhea
  • hormonal contraception
  • performance
  • health
  • Athlete Biological Passport
03

In context

Amenorrhea

80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.

This study's planned enrollment of 80 is above the median of 54 across 49 interventional studies indexed under Amenorrhea.

Browse Amenorrhea studies →

Lead sponsor

This is the only study on the registry with Université Paris-Saclay-Assistance publique des hôpitaux de Paris as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 30 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Group 1: high-level athletes (qualified for national/international championships and/or training at least 15 hours/week)
  • Group 2: recreational athletes who practice a regular physical activity

Exclusion criteria

Exclusion Criteria:

  • Participation in another trial
  • History of cardiac pathology
  • High blood pressure
  • History of ulcers and other gastrointestinal disorders
  • Myasthenia
  • Renal insufficiency
  • Person not affiliated or not benefiting from a social security system
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Female athletes

    highly trained subjects

    Other: Multidisciplinary monitoring of healthy women

  • Experimental
    Leisure sport women

    recreational sportswomen practicing regular physical activity

    Other: Multidisciplinary monitoring of healthy women

Interventions

  • OtherMultidisciplinary monitoring of healthy women

    Multidisciplinary monitoring

06

What researchers measure

Primary outcomes

  1. Change from baseline weight

    in kg, by impedancemeter

    Time frame: 6 months

  2. Change from baseline fat and lean mass

    in kg, by impedancemeter

    Time frame: 6 months

  3. Change from baseline height

    in cm, by height gauge

    Time frame: 6 months

  4. Change from baseline sex and stress hormones

    concentration of oestradiol, progesterone, testosterone, DHEA, cortisol, LH and FSH in mol/L

    Time frame: 6 months

  5. Change from baseline food intake

    food intake questionnaire to complete over 3 days, expressed in kcal/day

    Time frame: 6 months

  6. Change from baseline metabolic parameters

    concentration of blood glucose, blood lactate, lipid profile, insulin, GH, IGF1, T3, IgA, PRL and leptin in mol/L

    Time frame: 6 months

  7. Change from baseline respiratory parameters

    measure of FEV1 (forced expiratory volume in 1 second), expressed in % of vital capacity

    Time frame: 6 months

  8. Change from baseline inflammatory parameters

    concentration of cytokines (TNF-alpha, IL-6) in mol/L

    Time frame: 6 months

  9. Change from baseline executive function

    assessed by instability via static and dynamic postures (eyes open/closed) on platform

    Time frame: 6 months

  10. Change from baseline visual-spatial processing

    3 D mental rotation test, assessed by scores: range from 0 - 24, with 24 representing a perfect total score

    Time frame: 6 months

  11. Change from baseline attention and working memory

    Stroop Color Word Task, assessed by scores : range of interference from -15 - +15, with higher scores representing decreased selective attention

    Time frame: 6 months

  12. Change from baseline performance monitoring

    field performance test, performance expressed in time

    Time frame: 6 months

  13. Change from baseline Athlete Biological Passport (Group 2)

    assessed by analysis of the standardized parameters of the Athlete Biological Passport (WADA)

    Time frame: 6 months

  14. Change from baseline affects (Group 2)

    Positive Affect and Negative Affect Schedule (PANAS), assessed by scores. Positive Affect Score: range from 10 - 50, with higher scores representing higher levels of positive affect. Negative Affect Score: range from 10 - 50, with lower scores representing lower levels of negative affect.

    Time frame: 6 months

  15. Change from baseline anxiety (Group 2)

    Spielberger State-Trait Anxiety Inventory, assessed by scores: range from 20 - 80, with higher scores representing higher anxiety

    Time frame: 6 months

  16. Change from baseline Athlete Biological Passport (Group 1)

    assessed by analysis of the standardized parameters of the Athlete Biological Passport (WADA)

    Time frame: 8 months

  17. Change from baseline affects (Group 1)

    Positive Affect and Negative Affect Schedule (PANAS), assessed by scores. Positive Affect Score: range from 10 - 50, with higher scores representing higher levels of positive affect. Negative Affect Score: range from 10 - 50, with lower scores representing lower levels of negative affect.

    Time frame: 8 months

  18. Change from baseline anxiety (Group 1)

    Spielberger State-Trait Anxiety Inventory, assessed by scores: range from 20 - 80, with higher scores representing higher anxiety

    Time frame: 8 months

  19. Interview (Group 1)

    Self-confrontation interview for questioning the action

    Time frame: 8 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Ackerman KE, Singhal V, Baskaran C, Slattery M, Campoverde Reyes KJ, Toth A, Eddy KT, Bouxsein ML, Lee H, Klibanski A, Misra M. Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial. Br J Sports Med. 2019 Feb;53(4):229-236. doi: 10.1136/bjsports-2018-099723. Epub 2018 Oct 9. PubMed 30301734 ↗
  • Crewther BT, Cook CJ. The salivary testosterone response to a chance-determined contest is associated with face-gazing behaviours in athletic women. Horm Behav. 2018 Jul;103:107-110. doi: 10.1016/j.yhbeh.2018.06.011. Epub 2018 Jul 2. PubMed 29953884 ↗
  • Casey E, Reese M, Okafor E, Chun D, Gagnon C, Nigl F, Dhaher YY. Influence of Menstrual Cycle and Oral Contraceptive Phase on Spinal Excitability. PM R. 2016 Sep;8(9):860-8. doi: 10.1016/j.pmrj.2016.01.013. Epub 2016 Feb 10. PubMed 26872589 ↗
  • Cornelli U, Belcaro G, Cesarone MR, Finco A. Analysis of oxidative stress during the menstrual cycle. Reprod Biol Endocrinol. 2013 Aug 2;11:74. doi: 10.1186/1477-7827-11-74. PubMed 23915183 ↗
  • Eklund E, Berglund B, Labrie F, Carlstrom K, Ekstrom L, Hirschberg AL. Serum androgen profile and physical performance in women Olympic athletes. Br J Sports Med. 2017 Sep;51(17):1301-1308. doi: 10.1136/bjsports-2017-097582. Epub 2017 Jun 23. Erratum In: Br J Sports Med. 2021 Oct;55(19):e8. doi: 10.1136/bjsports-2017-097582corr1. PubMed 28646101 ↗
  • Emami F, Kordi Yoosefinejad A, Motealleh A. Comparison of static and dynamic balance during early follicular and ovulation phases in healthy women, using simple, clinical tests: a cross sectional study. Gynecol Endocrinol. 2019 Mar;35(3):257-260. doi: 10.1080/09513590.2018.1519788. Epub 2018 Oct 23. PubMed 30350735 ↗
  • Hausmann M, Slabbekoorn D, Van Goozen SH, Cohen-Kettenis PT, Gunturkun O. Sex hormones affect spatial abilities during the menstrual cycle. Behav Neurosci. 2000 Dec;114(6):1245-50. doi: 10.1037//0735-7044.114.6.1245. PubMed 11142657 ↗
  • Julian R, Hecksteden A, Fullagar HH, Meyer T. The effects of menstrual cycle phase on physical performance in female soccer players. PLoS One. 2017 Mar 13;12(3):e0173951. doi: 10.1371/journal.pone.0173951. eCollection 2017. PubMed 28288203 ↗
  • Kishali NF, Imamoglu O, Katkat D, Atan T, Akyol P. Effects of menstrual cycle on sports performance. Int J Neurosci. 2006 Dec;116(12):1549-63. doi: 10.1080/00207450600675217. PubMed 17145688 ↗
  • Kluft C, Leuven JA, Helmerhorst FM, Krans HM. Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment. Vascul Pharmacol. 2002 Aug;39(3):149-54. doi: 10.1016/s1537-1891(02)00304-x. PubMed 12616983 ↗
  • Langdeau JB, Day A, Turcotte H, Boulet LP. Gender differences in the prevalence of airway hyperresponsiveness and asthma in athletes. Respir Med. 2009 Mar;103(3):401-6. doi: 10.1016/j.rmed.2008.09.023. Epub 2008 Nov 21. PubMed 19027280 ↗
  • Lebrun CM, Petit MA, McKenzie DC, Taunton JE, Prior JC. Decreased maximal aerobic capacity with use of a triphasic oral contraceptive in highly active women: a randomised controlled trial. Br J Sports Med. 2003 Aug;37(4):315-20. doi: 10.1136/bjsm.37.4.315. PubMed 12893716 ↗
  • Nose-Ogura S, Yoshino O, Dohi M, Kigawa M, Harada M, Hiraike O, Onda T, Osuga Y, Fujii T, Saito S. Risk factors of stress fractures due to the female athlete triad: Differences in teens and twenties. Scand J Med Sci Sports. 2019 Oct;29(10):1501-1510. doi: 10.1111/sms.13464. Epub 2019 Jun 9. PubMed 31100189 ↗
  • Otaka M, Chen SM, Zhu Y, Tsai YS, Tseng CY, Fogt DL, Lim BH, Huang CY, Kuo CH. Does ovulation affect performance in tennis players? BMJ Open Sport Exerc Med. 2018 Jan 27;4(1):e000305. doi: 10.1136/bmjsem-2017-000305. eCollection 2018. Erratum In: BMJ Open Sport Exerc Med. 2018 Aug 21;4(1):e000305corr1. doi: 10.1136/bmjsem-2017-000305corr1. PubMed 29464104 ↗
  • Schaumberg MA, Jenkins DG, Janse DE Jonge XA, Emmerton LM, Skinner TL. Oral Contraceptive Use Dampens Physiological Adaptations to Sprint Interval Training. Med Sci Sports Exerc. 2017 Apr;49(4):717-727. doi: 10.1249/MSS.0000000000001171. PubMed 27898641 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2021; primary completion for May 2023, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2021
First posted
Aug 31, 2021
StartEst.
Sep 15, 2021
Primary completionEst.
May 31, 2023
CompletionEst.
May 31, 2025
Last update
Aug 31, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05028959
Lead sponsor
Université Paris-Saclay-Assistance publique des hôpitaux de Paris
Responsible party
Emmanuelle Duron (Head of Geriatry, Principal investigator, Université Paris-Saclay-Assistance publique des hôpitaux de Paris) — Principal investigator
First posted
Aug 31, 2021
Start date
Sep 15, 2021 (estimated)
Primary completion
May 31, 2023 (estimated)
Completion
May 31, 2025 (estimated)
Last update
Aug 31, 2021

Study contacts

Emmanuelle DURON, PU-PH
Contact
emmanuelle.duron@aphp.fr
33144083503
Christine Le-Scanff, PU
Contact
christine.le-scanff@universite-paris-saclay.fr
33169156198

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion